Apraclonidine recalls
The FDA has published 2 recalls involving Apraclonidine since 2022. The latest was reported on 7 Jun 2023. Most were for manufacturing (cgmp) deviations. Akorn has the most recalls in this group. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls2since 2022
Last 12 months0reported
Class I00% of total
Ongoing1latest 7 Jun 2023
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 2 100%Class III 0 0%
Why apraclonidine is recalled
Companies
By year
Ongoing apraclonidine recalls
1 active| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Apraclonidine Ophthalmic Solution recalled by Akorn | Akorn | Potency & Assay | Nationwide |
All apraclonidine recalls, newest first
2 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Apraclonidine Ophthalmic Solution recalled by Akorn | Akorn | Potency & Assay | Nationwide |
| Drug | CLASS II | Aparaclonidine Ophthalmic Solution 0.5% as base recalledApraclonidine | Mckesson Medical-Surgical Inc. Corporate Office | Manufacturing (CGMP) Deviations | Nationwide |
Should you stop taking Apraclonidine?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.